Pfizer Inc. logo
Pfizer Inc. (PFE)
Compare

Pfizer Inc. (PFE) Share Buybacks

The buybacks for Pfizer Inc. (PFE) is $2.00 Billion with a year-over-year change of -77.44%. Share buybacks (stock repurchases) represent cash spent by the company to buy back its own shares in the open market, reducing shares outstanding and returning capital to shareholders.

PFE Buybacks Chart

PFE Buybacks
$2.00B-59.97% 20Y
Zoom

Current Buybacks

$2.00B

$2.00 Billion

Year-over-Year Change

-77.44%

vs. $8.87B prior year

Historical Data

24

Years of data available

Annual Buybacks History

YearBuybacksYoY Change% Change
2022$2.00B$-6.87B-77.44%
2019$8.87B$-3.33B-27.32%
2018$12.20B+$7.20B+143.96%
2017$5.00B+$00.00%
2016$5.00B$-1.16B-18.83%
2015$6.16B+$1.16B+23.20%
2014$5.00B$-11.29B-69.31%
2013$16.29B+$8.06B+97.98%
2012$8.23B$-772.00M-8.58%
2011$9.00B+$8.00B+800.00%
2010$1.00B+$500.00M+100.00%
2008$500.00M$-9.49B-95.00%
2007$9.99B+$3.02B+43.20%
2006$6.98B+$3.18B+83.80%
2005$3.80B$-2.86B-42.98%
2004$6.66B$-6.38B-48.92%
2003$13.04B+$8.04B+160.95%
2002$5.00B+$1.33B+36.32%
2001$3.67B+$2.66B+264.68%
2000$1.00B$-1.54B-60.46%
1999$2.54B+$365.00M+16.77%
1998$2.18B+$1.59B+271.50%
1997$586.00M+$559.00M+2070.37%
1996$27.00M
Data as of Wednesday, June 10, 2026

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

New York City, NY
81,000 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Albert Bourla